Ionis Pharmaceuticals (NASDAQ: IONS) EVP granted 7,500 stock options

Rhea-AI Filing Summary

Ionis Pharmaceuticals executive Holly Kordasiewicz reported a stock option grant under the company’s equity incentive plan. On 01/02/2026, she received a non-qualified stock option to purchase 7,500 shares of Ionis Pharmaceuticals common stock at an exercise price of $79.67 per share.

According to the filing, none of these options were exercisable on the grant date. 25% of the option shares will vest and become exercisable on 01/02/2027, with the remaining shares vesting in 36 equal monthly installments over the following three years, so full vesting occurs over four years. After this grant, Kordasiewicz beneficially owned 16,600 stock options in total, held directly.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Kordasiewicz Holly B.

(Last) (First) (Middle)

2855 GAZELLE COURT

(Street)

CARLSBAD CA 92010

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
IONIS PHARMACEUTICALS INC [ IONS ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	EVP, Chief Development Officer

3. Date of Earliest Transaction (Month/Day/Year)
01/02/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)
01/06/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Non-Qualified Stock Option (right to buy)	$79.67	01/02/2026		A		7,500		01/02/2027(1)	01/01/2036	Common Stock	7,500	$0.0	16,600	D

Explanation of Responses:

1. Grant on 01/02/2026 to reporting person of stock options under the Ionis Pharmaceuticals, Inc. Amended and Restated 2011 Equity Incentive Plan. Following this transaction, the option was exercisable as to 0 shares on 01/02/2026. 25% of the shares subject to the option will vest and become exercisable on 01/02/2027. Thereafter, the remaining shares subject to the option will vest and become exercisable in 36 equal monthly installments over the next 3 years.

	By: Patrick R. O'Neil, attorney-in-fact For: Holly Kordasiewicz	01/20/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Ionis Pharmaceuticals (IONS) report for Holly Kordasiewicz?

The filing reports a grant of non-qualified stock options to Holly Kordasiewicz, Ionis Pharmaceuticals’ EVP and Chief Development Officer, on 01/02/2026 under the company’s equity incentive plan.

How many Ionis Pharmaceuticals shares are covered by the new stock option grant?

The non-qualified stock option covers 7,500 shares of common stock of Ionis Pharmaceuticals.

What is the exercise price and vesting schedule of the new Ionis (IONS) stock options?

The option has an exercise price of $79.67 per share. 25% of the shares vest on 01/02/2027, and the remaining shares vest in 36 equal monthly installments over the next three years.

When do the Ionis Pharmaceuticals options granted on 01/02/2026 become exercisable?

The option was exercisable as to 0 shares on 01/02/2026. 25% becomes exercisable on 01/02/2027, with the rest becoming exercisable through 36 monthly installments over the following three years.

How many Ionis Pharmaceuticals options does Holly Kordasiewicz hold after this transaction?

After the reported grant, Holly Kordasiewicz beneficially owned 16,600 derivative securities (stock options) of Ionis Pharmaceuticals, held directly.

Under which plan were the Ionis (IONS) stock options granted to Holly Kordasiewicz?

The options were granted under the Ionis Pharmaceuticals, Inc. Amended and Restated 2011 Equity Incentive Plan.